Technology Dev Core: The Center for Advancing Point of Care Technologies in Heart, Lung, Blood and Sleep Diseases

项目概要/摘要-技术开发核心 中心的目标是推进床旁护理技术（CAPCaT）在心脏，肺， 血液和睡眠疾病（HLBS）是开发和优化新的护理点技术 （POCT）以改善与HLBS相关的病症的诊断和管理。这些 疾病代表了美国发病率和死亡率的主要来源。 从在专门的测试设施中提供护理到 从医疗中心到远程监控和家庭护理。CAPCaT 是基于非常成功的医疗产品孵化器，马萨诸塞州医疗器械 马萨诸塞州（UMass）洛厄尔和伍斯特大学发展中心（M2 D2） 校园。麻省大学洛厄尔分校在工程和商业方面具有特别的优势，而 伍斯特校区设有马萨诸塞大学医学院，这是第一个也是唯一一个公立 学术健康科学中心在联邦马萨诸塞州。M2 D2有一个 为早期医疗设备提供一系列支持服务的基础设施到位 公司工作在各种各样的医疗适应症，并在不同的节点的临床 在乎CAPCaT将扩展M2 D2，具体关注HLBS疾病和POCT。的 技术开发核心将从以下方面识别、选择和支持新的有价值的项目： 通过早期的临床试验。选择将基于性能和潜力， 临床影响，并将支持将利用强大的现有资源在马萨诸塞州大学收集 洛厄尔和伍斯特，以帮助发展现有的原型，以点的临床 验证。

PROJECT SUMMARY/ABSTRACT – TECHNOLOGY DEVELOPMENT CORE The goal of the Center for Advancing Point of Care Technologies (CAPCaT) in Heart, Lung, Blood, and Sleep Diseases (HLBS) is to develop and optimize novel point of care technologies (POCT) to improve the diagnosis and management of disorders relating to HLBS. These disorders represent a major source of morbidity and mortality in the U.S. POCT represents an important tool in the transformation from delivering care in specialized testing facilities to the bedside, and also from medical centers to remote monitoring and home-based care. CAPCaT is based on the highly successful medical product incubator, the Massachusetts Medical Device Development Center (M2D2) at the University of Massachusetts (UMass) Lowell and Worcester campuses. UMass Lowell has particular strengths in engineering and business, while the Worcester campus houses the UMASS Medical School, which is the first and only public academic health sciences center in the Commonwealth of Massachusetts. M2D2 has an infrastructure in place that provides a range of support services to early-stage medical device companies working in a wide variety of medical indications, and at different nodes of clinical care. CAPCaT will expand on M2D2 with a specific focus HLBS disorders and on POCT. The Technology Development Core will identify, select, and support new meritorious projects from prototype through early clinical testing. Selection will be based on performance and potential for clinical impact, and will support will utilize a strong collection of existing resources at UMass Lowell and Worcester in order to help develop existing prototypes to the point of clinical validation.